Category: Products

Cosette Pharmaceuticals, Inc. (“Cosette”), a U.S.-based specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved EVOXAC^® (cevimeline HCl) oral solution for the treatment of symptoms of dry mouth in adults with Sjögren’s disease.

Cosette Pharmaceuticals, Inc., a U.S.-based, fully integrated pharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has approved Cosette's Abbreviated New Drug Application (ANDA) for the first generic version of CIPRO® HC (ciprofloxacin 0.2% HCl and hydrocortisone 1% otic suspension), with 180 days of Competitive Generic Therapy (CGT) exclusivity. Cosette has commenced commercial shipments, triggering the 180 days of market exclusivity.

Cosette Pharmaceuticals, Inc. ("Cosette") announced that the U.S. Food and Drug Administration (FDA) has approved the Abbreviated New Drug Applications (ANDA) for the first generic version of RECTIV® (nitroglycerin) ointment, 0.4%, with 180 days Competitive Generic Therapy (CGT) exclusivity. Cosette will imminently commence commercial shipments, triggering the 180 days exclusivity.

Cosette Pharma announced today that it has entered into an agreement with Mark Cuban Cost Plus Drug Company, PBC (Cost Plus Drugs) to offer CLOMID® (clomiPHENE citrate) 50mg tablets at a low cash price via the Cost Plus Drugs online pharmacy.

Cosette Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved its abbreviated new drug application (ANDA) for a generic version of MetroGel-Vaginal® (metronidazole vaginal gel 0.75%) by Bausch Health US, LLC.

Apurva Saraf, President and CEO of Cosette, stated "This launch is further evidence of Cosette's ability to partner globally and bring important drugs to the market, and furthers our transformation into a specialty pharmaceutical company.  We stay true to our firm belief of Innovating Every Day, to be a trusted partner of choice, and to continue the important work of serving U.S. patients and prescribers.”

Cosette Pharmaceuticals, Inc ("Cosette") announced that the U.S. Food and Drug Administration (FDA) has approved the Abbreviated New Drug Applications (ANDA) for Metronidazole Gel USP, 1%.

Cosette Pharmaceuticals, Inc began shipping Griseofulvin Oral Suspension, 125 mg/5 mL (0713-0850-04) into all channels in the United States.